Navigation Links
FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
Date:6/20/2012

SAN DIEGO, June 20, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting and presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium, in San Diego, June 22-24. FirstMark will showcase the groundbreaking research and data that is the foundation for PREvent. PREvent is the first and only multiple biomarker blood test on the market that accurately predicts near term (2-3 years) risk of myocardial infarction (MI) and death for coronary artery disease (CAD) patients. PREvent is an exciting development in cardiovascular patient management, addressing the unmet need to assess the risk of near term MI.

Dr. Sergey Sikora, Sr. Vice President of FirstMark, will present the research and data at the Symposium at 12:00 p.m. – 1:00  p.m., Sunday, June 24th, Paradise Point Resort at Mission Bay, Garden Room. Dr. Sikora is co-creator of a PREvent, along with noted cardiologists and researchers Dr. Arshed Quyyumi at Emory University, and Dr. Stephen Epstein at MedStar Health Research Institute. FirstMark will be exhibiting at the symposium on Friday, June 22nd, and Saturday, June 23rd.

"We look forward to the opportunity to present to the family physicians in attendance at the symposium," said Dr. Sikora. "The symposium focuses on novel technologies that determine patients at risk for particular medical conditions, in order to control or prevent further complications. This event provides a perfect setting for FirstMark to share the remarkable research data and benefits of PREvent. We believe many of the physicians that are in attendance will find PREvent of interest with strong potential for clinical application for their CAD patients."

PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annualized event rate of MI or death for 18.2% of significant CAD patients with all three biomarkers elevated as compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk patients.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit FirstMarkPREvent.com.

Media Contact: Deborah Moore FirstMark, 858-458-0866 x 113, dmoore@thefirstmark.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

 


'/>"/>
SOURCE FirstMark
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
2. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
3. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
4. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
5. 2012 AAPS National Biotechnology Conference heads to San Diego
6. Harris Lewin elected to National Academy of Sciences
7. Professor known for work with hunter-gatherers elected to American Academy of Arts and Sciences
8. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
9. Family values
10. Discovery of a new family of key mitochondrial proteins for the function and viability of the brain
11. Starting a family does not encourage parents to eat healthier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology: